At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 206 enrolled
Drug / intervention
Currently Marketed PureVision Contact Lens. +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Product Performance of the Redesigned Bausch & Lomb PureVision® Contact Lens (Test) Compared to the Currently Marketed Bausch & Lomb PureVision® Contact Lens (Control) When Worn on an Extended Wear Basis.
In Brief
A Phase 3 clinical trial evaluating Currently Marketed PureVision Contact Lens. and Alternate Design of the PureVision Contact Lens. for Myopia. Completed, enrolled 206 participants across 2 sites in 2 countries.
Detailed Summary
The objective of this study is to evaluate the performance of the PureVision Lens designs when worn on a 30-day continuous wear basis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesMalaysia, Philippines
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
Primary CompletionFeb 2008
First PostedApr 2008
Study CompletionJun 2008
TodayJul 2026
First PostedApr 18, 2008
Enrollment StartDec 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.2 years ago
Interventions
Currently Marketed PureVision Contact Lens.device
Contact lens for continuous wear
Alternate Design of the PureVision Contact Lens.device
Contact lens for continuous wear